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1 |  INTRODUCTION
Angelman syndrome (AS) is a rare neurodevelopmental disor-
der with an estimated prevalence of 1 in 12,000 to 1 in 20,000 
people in the United States (NORD, 2018). Individuals with 
AS present with intellectual disability, severe movement or 
balance disorder, behavioral issues, seizures, sleep distur-
bances, and speech impairment (Williams et al., 2006). AS 
has a significant healthcare burden and requires lifelong 
support from a network of specialist and caregivers.
AS is caused by loss of UBE3A expression in neu-
rons. There are four molecular etiologies: deletion on the 
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Abstract
Background: The objective of this study is to describe healthcare resource utilization 
(HRU) and supportive therapy utilization (STU) among individuals with Angelman 
syndrome (AS), and to compare such usage by molecular etiology.
Methods: Participants were categorized into deletion and non‐deletion genotypes. 
Statistical differences were assessed using an independent samples t test.
Results: Data were available on 302 individuals. Mean age of participants was 
5.5 years, 92% of whom were less than 13 years, and 71% had the deletion etiology. 
About 68% of participants had at least one hospitalization since birth to enrollment in 
the study; the average number of hospitalizations during that time period was 2.3 and 
average length of stay was 4.5 days. The most common reasons for hospitalization 
were seizures, lower respiratory infections, and surgery. The most common reasons 
for surgery were myringotomy, strabismus surgery, tonsillectomy or adenoidec-
tomy, and gastrostomy tube insertion/fundoplication. Anticonvulsants, gastroesoph-
ageal reflux disease, sleep, and behavioral medications were the most commonly  
prescribed drugs. STU was high among individuals with AS.
Conclusions: This study shows that individuals with AS have high HRU/STU, and 
apart from a few differences, HRU/STU was similar across molecular etiology. 
These results reflect usage in younger individuals and studies that describe HRU/
STU in older individuals are needed.
K E Y W O R D S
healthcare burden, healthcare costs, healthcare resource utilization, medical economics, supportive 
therapy utilization
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maternally inherited copy of chromosome 15q11.2q13.1 
(~70% of the cases), paternal uniparental disomy (UPD) for 
the same chromosomal region (2%–7% of cases), imprint-
ing defect (ID; 3%–5% of cases), and pathogenic variants in 
the maternal UBE3A allele (10% of cases) (Clayton‐Smith 
& Laan, 2003; Williams et al., 2006). While all cases of AS 
result in severe global developmental delay and intellectual 
disability, those with a deletion are more severely affected 
than those without, and individuals with deletion type are 
more likely to have microcephaly, poor linear growth, sei-
zures, and more severe motor, cognitive, and communica-
tion difficulties (Gentile et al., 2010; Lossie et al., 2001; 
Moncla et al., 1999; Tan et al., 2011; Varela, Kok, Otto, & 
Koiffmann, 2004).
Currently, there is no approved treatment for AS and 
medical management is focused on symptomatic treatment 
to address the complications of AS and is accompanied by 
supportive therapies (e.g. physical, occupational, speech, and 
behavioral therapies). However, there are limited data on the 
utilization of healthcare resources and supportive therapies 
in the AS community. This study aims to examine healthcare 
resource utilization (HRU) and supportive therapy utilization 
(STU) among individuals with AS and to explore whether 
there are differences among individuals with AS due to dif-
ferent molecular etiologies. HRU is defined as hospitaliza-
tion, surgery, and medication use, and STU includes early 
childhood intervention, as well as physical, occupational, and 
speech therapy programs. To evaluate both HRU and STU, 
we used data collected from the AS Natural History Study 
(ASNHS) baseline visits.
2 |  MATERIAL AND METHODS
2.1 | Ethics approval
This study was approved by the institutional review boards at 
each of the institutions where the data were obtained.
2.2 | Data
The ASNHS, conducted by the Angelman, Rett, and Prader–
Willi Syndromes Consortium of the National Institute of 
Health (NIH) Rare Diseases Clinical Research Network 
(Clini calTr ials.gov identifier: NCT00296764), was a longitu-
dinal observational study on the developmental progress, be-
havior, and medical morbidity of individuals with AS (Tan et 
al., 2011). Individuals were recruited at six study sites across 
the United States (Rady Children's Hospital San Diego, 
Texas Children's Hospital, Vanderbilt University Medical 
Center, Greenwood Genetic Center, Cincinnati Children's 
Hospital Medical Center, and Boston Children's Hospital) 
between 2006 and 2014. Inclusion criteria were a molecular 
diagnosis of AS and participants between the ages of 1 day 
and 60  years. Individuals were excluded from the study if 
they had a comorbid disorder that was not a known feature 
of AS or severe prematurity (less than 28 weeks gestation). A 
total of 302 individuals with AS were enrolled in this study.
Historical, medical, and resource utilization data were col-
lected from the caregivers of AS individuals since birth until 
the age of enrollment. HRU and STU data collected included 
information on hospitalization, reasons for hospitalization, and 
length of stay (LOS). Surgery data included the date and type 
of surgery performed. Data were also collected on the use of 
prescription and non‐prescription medications, including rea-
sons for use. Information on STU included use of early child-
hood intervention, physical therapy, occupational therapy, and 
speech therapy. For each STU, information was collected on 
whether therapy was received, whether it was conducted in 
school or out of school, and the frequency of therapy.
2.3 | Statistical analyses
Analyses were performed on the HRU and STU data collected 
at baseline, which captured utilization from birth until the age 
of enrollment. To assess differences by molecular etiologies, 
individuals were stratified into deletion and non‐deletion co-
horts. The non‐deletion cohort included UPD, ID, and UBE3A 
mutations. Key outcomes of interest (hospitalization, surgery, 
medication use, and STU) were summarized for the overall 
population and by molecular etiology. Other variables of in-
terest, including demographics, medical problems, and clini-
cal seizure history, were summarized for the overall cohort 
and by molecular etiology. For continuous variables, data 
were presented as mean, median, standard deviation (SD), and 
95% confidence interval (CI), as applicable. For categorical 
variables, data were presented as frequencies and percentages. 
Statistical differences between the deletion and non‐deletion 
cohorts were examined using an independent samples t test 
or Fisher's exact test, as appropriate. A nominal p‐value of 
0.05 or below was considered statistically significant. Missing 
data were not imputed. All statistical analyses were performed 
using SAS® Version 9.4 or higher for Windows.
3 |  RESULTS
3.1 | Descriptive demographic, medical, and 
seizure history
Table 1 shows descriptive demographic information, medical 
problems, and clinical seizure history for the overall cohort 
and stratified by molecular etiology. Of the 302 participants 
included in the analyses, three were included only in the over-
all cohort because it was not documented if they had a deletion. 
There were 212 participants (71%) with a deletion molecular 
subtype and 87 participants (29%) without a deletion. Among 
the non‐deletion etiology, 33 (38%) had a UBE3A mutation, 
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29 (33%) had UPD, 22 (25%) had ID, and 3 (3%) had abnor-
mal DNA methylation without further characterization of the 
molecular etiology. For the overall cohort, the mean age at AS 
diagnosis was 2 years (SD: 3 years) and about 52% of the par-
ticipants were female. Mean age at baseline visit was 5.5 years 
(SD: 5.9  years). Figure 1 presents age distribution, 92% of 
whom were less than 13 years of age; half of the sample was 
younger than 4 years. A total of 68% of participants had a his-
tory of clinical seizures at baseline, and the mean age at first 
seizure was 1.7 years (SD = 1.4 year). Among those who had 
seizures, the most common types were atonic/drop attacks 
(42%), tonic/generalized tonic (36%), and absence (35%). The 
most commonly reported medical issues since birth were sleep 
issues (82%), gastroesophageal reflux disease (GERD; 66%), 
otitis media (51%), strabismus (50%), and gagging (50%).
Deletion and non‐deletion individuals had similar char-
acteristics, except for a few notable differences. Specifically, 
deletion individuals were diagnosed earlier (1.7  years vs. 
T A B L E  1  Descriptive demographic, medical, and seizure history among individuals with AS by molecular etiology
Variable
Overall 
N = 302
Deletion 
N = 212
Non‐deletion 
N = 87 p‐valuea
Molecular diagnosis, n (%)
Abnormal DNA methylation 6 (2) — 3 (3) —
UBE3A mutation 33 (11) — 33 (38)  
UPD 29 (10) — 29 (33)  
Imprinting defect 22 (7) — 22 (25)  
Deletion 212 (70) 212 (100) —  
Age at baseline, years, mean (SD) 5.5 (5.9) 5.5 (6.5) 5.6 (4.2) 0.9338
Age at diagnosis, years; mean (SD) 2 (3) 1.7 (3.1) 2.9 (2.5) 0.0007
Male, n (%) 145 (48) 96 (45) 46 (53) 0.2527
Female, n (%) 157 (52) 116 (55) 41 (47)  
Seizure history, n (%)
Clinical seizures 199 (68) 156 (77) 42 (49) <0.0001
Age at first seizure years; mean (SD) 1.7 (1.4) 1.5 (1.2) 2.3 (1.6) 0.0025
Seizure typeb, n (%)
Absence 70 (35) 54 (35) 16 (38) 0.7177
Myoclonic 40 (20) 32 (21) 8 (19) 1.0000
Atonic/drop attacks 83 (42) 61 (40) 21 (50) 0.2203
Tonic/generalized tonic 71 (36) 64 (41) 7 (17) 0.0035
Generalized clonic 46 (23) 42 (27) 4 (10) 0.0223
Other 53 (27) 43 (28) 9 (21) 0.5538
Had ketogenic diet to control seizures 5 (3) 5 (3) —  
Other medical history, n (%)
Otitis media 149 (51) 98 (48) 50 (59) 0.1210
Pneumonia 72 (25) 50 (25) 22 (27) 0.7650
Gastrointestinal reflux
Never formally diagnosed 59 (20) 39 (19) 20 (23) 0.1312
Diagnosed 136 (46) 91 (44) 45 (52)  
Vomiting with feeds 61 (21) 43 (21) 17 (20) 0.8751
Gagging 146 (50) 102 (50) 42 (50) 1.0000
Tight heels cords/toe walking 109 (40) 70 (37) 37 (45) 0.2809
Strabismus 147 (50) 116 (57) 31 (37) 0.0028
Sleep issues 241 (82) 168 (81) 71 (85) 0.6129
Note: Percentages have been rounded to the nearest integer.
Abbreviations: AS, Angelman syndrome; SD, standard deviation; UPD, uniparental disomy.
ap‐values comparing deletion versus non‐deletion cohort were performed using an independent samples t test or Fisher's exact test, as appropriate. 
bIndividuals can be counted in more than one seizure type. 
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2.9  years; p  =  0.0007) and were more likely to have stra-
bismus (57% vs. 37%; p  =  0.0028). Deletion individuals 
were also more likely to have clinical seizures (77% vs. 
49%; p < 0.001) with a mean age at first clinical seizure of 
1.5  years compared to 2.3  years for non‐deletion individu-
als (p = 0.0025). In addition, individuals with deletion were 
more likely to have tonic/generalized tonic (p = 0.0035) and 
generalized clonic (p = 0.0223) seizures compared to non‐de-
letion individuals.
3.2 | Healthcare resource utilization
Tables 2 and 3 present the HRU for the AS cohort overall 
and stratified by molecular etiology. Sixty‐eight per cent of 
participants had at least one hospitalization since birth to 
enrollment into the study; the mean number of hospitaliza-
tions during that time period was 2.3 (95% CI: 2.1–2.5). 
The average LOS was 4.5  days (95% CI: 3.8–5.2). The 
most common reasons for hospitalization were seizures 
(40%), lower respiratory infections (21%), and surgery 
(11%; Table 3). Deletion and non‐deletion individuals had 
similar rates of hospitalization, number of hospitalizations, 
and LOS. Reasons for hospitalization were similar across 
molecular etiologies except for seizures, which was sig-
nificantly more common among the deletion cohort at 48% 
compared to the non‐deletion cohort at 21% (p = 0.0004; 
Table 3).
Fifty‐seven per cent of participants with AS had at least one 
surgery (Table 2). The most common surgeries were insertion 
of ear tubes (34%), correction of strabismus (30%), tonsillec-
tomy and adenoidectomy (25%), and gastrostomy tube inser-
tion/fundoplication (8%; Table 3). Mean number of surgeries 
since birth to time of enrollment in the study was 1.7 (95% 
CI: 1.6–1.8). Deletion and non‐deletion individuals had similar 
rates, mean number, and reasons for surgery except for stra-
bismus, which was significantly more common in the deletion 
cohort compared to the non‐deletion cohort (36% vs. 18%; 
p = 0.0184).
About 80% of participants used at least one prescription 
medication (Table 2). The mean number of prescription 
medications used was 2.8 (SD: 2.0). Anticonvulsants were 
the most common prescription medications that were used, 
with clonazepam (24%), levetiracetam (22%), valproic acid 
(22%), and topiramate (16%) being the most common. This 
F I G U R E  1  ASNHS, AS Natural History Study. Age distribution at baseline (time of enrollment in the ASNHS study). 
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was followed by the use of medications for GERD: ranitidine 
(24%) and lansoprazole (19%) and medications for sleep or 
behavior: melatonin (42%), clonidine (14%), diphenhydr-
amine (8%), and risperidone (7%) (Table 3). Prescription 
medication use was higher among the deletion cohort com-
pared to the non‐deletion group (85% vs. 71%; p = 0.0084). 
However, specific medications did not differ between cohorts 
(Table 3) except for levetiracetam, which was used signifi-
cantly more in the deletion cohort (p = 0.0136).
3.3 | Supportive therapy utilization
Table 2 also presents STU among individuals with AS. In 
general, the use of therapy was high, with 95% of individu-
als receiving early child intervention, 90% receiving physical 
therapy, 88% receiving occupational therapy, and 86% re-
ceiving speech therapy (either school‐ or non‐school‐based). 
STU did not differ between the deletion and non‐deletion 
cohorts.
4 |  DISCUSSION
To our knowledge, this is the first published study to sys-
tematically characterize the healthcare burden of AS in the 
United States of America (USA). This is also the first pub-
lished study to analyze the healthcare burden among indi-
viduals with AS by molecular etiology. A targeted review 
of the literature identified only two published studies that 
have assessed healthcare utilization among individuals with 
AS (Domínguez‐Berjón, Zoni, Esteban‐Vasallo, Sendra‐
Gutierrez, & Astray‐Mochales, 2018; Thomson, Glasson, & 
Bittles, 2006). Domínguez‐Berjón et al. (2018) examined 49 
individuals with AS in Spain with a median age of 17 years 
(interquartile range 14); however, only 32 were confirmed to 
have AS by molecular testing. Thomson et al. (2006) studied 
34 individuals with AS in Western Australia with a mean age 
of 22 years (range 6.5–39 years), but only 14 were confirmed 
to have AS by molecular testing. These two studies had rel-
atively few individuals with genetically confirmed AS and 
described only the incidence and reasons for hospitalizations 
without analyzing the differences among individuals with 
different molecular etiologies. As such, our study makes a 
significant contribution by characterizing the current medical 
and therapeutic needs of a relatively large sample of indi-
viduals with genetically confirmed AS in the USA.
This study suggests that individuals with AS experi-
ence significant healthcare burden. Individuals with AS are 
known to experience seizures, motor, speech, behavior, and 
cognition issues, and this was reflected in the vast array of 
medical services and supportive therapy used in our sam-
ple. More than half of the sample had at least one episode 
of hospitalization. These results are consistent with the two 
other AS studies that examined healthcare resource utili-
zation. Domínguez‐Berjón et al. (2018) found that 86% of 
individuals with AS had at least one hospitalization. Major 
T A B L E  2  HRU and STU for overall cohort and by molecular etiology
Descriptive
Overall 
N = 302
Deletion 
N = 212
Non‐deletion 
N = 87 p‐valuea
HRU
Hospitalization
Ever been hospitalized, n (%) 205 (68) 146 (69) 57 (66) 0.5875
Number of hospitalization, mean (95% CI) 2.3 (2.1–2.5) 2.3 (2.0–2.5) 2.4 (2–2.9) 0.7099
Length of stay, mean (95% CI) 4.5 (3.8–5.2) 4.1 (3.4–4.9) 5.5 (3.9–7.2) 0.1300
Surgery
Ever had surgery, n (%) 172 (57) 119 (56) 51 (59) 0.7022
Number of surgeries, mean (95% CI) 1.7 (1.6–1.8) 1.7 (1.5–1.9) 1.7 (1.5–1.9) 1.0000
Medication use
Ever used prescription medications, n (%) 245 (81) 181 (85) 62 (71) 0.0084
Number of prescription medications, mean (SD) 2.8 (2.0) 2.7 (1.8) 3.2 (2.3) 0.1242
STU
Early childhood intervention, n (%) 279 (95) 196 (94) 81 (96) 1.0000
Physical therapy, n (%) 263 (90) 190 (92) 71 (86) 0.0837
Occupational therapy, n (%) 255 (88) 181 (87) 72 (88) 0.5981
Speech therapy, n (%) 251 (86) 175 (85) 74 (89) 0.7332
Abbreviations: CI, confidence interval; HRU, healthcare resource utilization; STU, supportive therapy utilization.
ap‐values comparing deletion versus non‐deletion cohort were performed using an independent samples t test or Fisher's exact test, as appropriate. 
bIncludes prescription medications used by more than 10 individuals. 
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causes of hospitalization in our study were seizures, lower 
respiratory infection (e.g. pneumonia, bronchitis), or sur-
gery. The commonly reported reasons for hospitalization in 
the Domínguez‐Berjón et al. (2018) study were oral‐dental 
care, seizures, orthopedic problems, and acute respiratory 
disorders. Thomson et al. (2006) reported a median number 
of hospitalizations of 5.5 per person and the most common 
reasons for hospitalization in their cohort were epilepsy, 
gastrointestinal disorders, and dental issues. The magnitude 
of hospitalization was different between this study and the 
Spanish study. Specifically, we found a lower rate of overall 
hospitalization (68% vs. 86%) but a higher rate of seizure‐re-
lated hospitalizations (40% vs. 20%) compared to the Spanish 
study. This could be because we did not consider outpatient 
dental cleanings or restorations as “hospitalization”, or it 
could reflect differences in the healthcare practices between 
the two countries. Additionally, the individuals in our cohort 
are younger (median age: 3 years) compared to those in the 
T A B L E  3  Most frequent reasons for HRU for overall cohort and by molecular etiology
Descriptive
Overall 
N = 302
Deletion 
N = 212
Non‐deletion 
N = 87 p‐valuea
Hospitalization reasons, n (%)
Seizure 83 (40) 70 (48) 12 (21) 0.0004
Lower respiratory infection 43 (21) 28 (19) 15 (26) 0.3390
Surgery 22 (11) 17 (12) 4 (7) 0.4449
Other infection 18 (9) 11 (8) 7 (12) 0.2836
Dehydration 16 (8) 12 (8) 4 (7) 1.0000
Tonsillectomy and adenoidectomy 13 (6) 7 (5) 6 (11) 0.1978
Surgery reasons,  n (%)
Myringotomy 59 (34) 39 (33) 20 (39) 0.4827
Strabismus 52 (30) 43 (36) 9 (18) 0.0184
Tonsillectomy or adenoidectomy 43 (25) 25 (21) 17 (33) 0.1197
G‐tube or fundoplication 14 (8) 8 (7) 6 (12) 0.3604
Inguinal hernia 10 (6) 7 (6) 2 (4) 0.7257
Medication reasons
AED, n (%)
Clonazepam 72 (24) 55 (26) 16 (18) 0.1805
Levetiracetam 67 (22) 55 (26) 11 (13) 0.0136
Valproic acid 66 (22) 49 (23) 17 (20) 0.5423
Topiramate 48 (16) 38 (18) 9 (10) 0.1170
Lamotrigine 39 (13) 28 (13) 11 (13) 1.0000
Phenobarbital 32 (11) 25 (12) 7 (8) 0.4137
Diazepam 19 (6) 18 (8) 1 (1) 0.0173
GERD, n (%)
Ranitidine 72 (24) 44 (21) 27 (31) 0.0722
Lansoprazole 56 (19) 39 (18) 17 (20) 0.8706
Metoclopramide 35 (12) 24 (11) 11 (13) 0.8432
Omeprazole 28 (10) 17 (8) 11 (13) 0.2734
Sleep/behavior, n (%)
Melatonin (OTC) 126 (42) 89 (42) 36 (41) 1.0000
Clonidine 41 (14) 23 (11) 17 (20) 0.0603
Diphenhydramine (OTC) 24 (8) 17 (8) 11 (13) 0.3543
Risperidone 20 (7) 11 (5) 9 (10) 0.1265
Constipation/laxative, n (%)
Polyethylene glycol 46 (15) 32 (15) 13 (15) 1.0000
Laxative (others) 17 (6) 13 (6) 4 (5) 0.7855
Abbreviation: AED, Antiepileptic drugs; GERD, gastroesophageal reflux disease; OTC: Over‐the‐counter.
ap‐values comparing deletion versus non‐deletion cohort were performed using an independent samples t test or Fisher's exact test, as appropriate. 
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Spanish study (median age: 17 years) which could also ex-
plain differences in hospitalization rates.
We also found that use of prescription and non‐prescrip-
tion medication was high among individuals with AS, with 
the types of medications reflecting the major medical prob-
lems experienced (e.g. sleep disorders, seizures, gastrointes-
tinal problems). The type of seizure medications used in this 
study were similar to those reported in published literature 
(Fiumara, Pittala, Cocuzza, & Sorge, 2010; Williams et al., 
2006). We observed a significant use of melatonin and di-
phenhydramine in this study, suggesting that sleep disorders 
are a major issue in this population.
This is the first published study to report STU among in-
dividuals with AS. Approximately, 86%–96% of the partici-
pants in our study had physical, occupational, and/or speech 
therapy, suggesting the profound impact that AS has on an 
individual's global functioning.
The secondary objective of this study was to assess 
whether there were differences in healthcare utilization 
across individuals with deletion and non‐deletion etiology. 
Previous studies suggested that individuals with deletion 
experienced higher rates of seizures, feeding difficulties, 
microcephaly, and pronounced motor, cognitive, and com-
munication difficulties (Lossie et al., 2001; Moncla et al., 
1999; Varela et al., 2004). In our sample, the deletion co-
hort was significantly more likely to have seizures, and their 
seizures started at a younger age. However, other clinical 
characteristics were comparable across groups. Notably, 
HRU and STU between the deletion and non‐deletion co-
horts were similar except for seizure‐related hospitalization, 
strabismus surgery, and use of levetiracetam. Hence, despite 
suggestions in the literature of a slightly more severe pheno-
type, this analysis demonstrates that the healthcare burden 
across the two etiologies is comparable. Future studies that 
investigate how this burden varies with age would help as-
sess if healthcare needs remain similar across the two etiol-
ogies over time.
This study has several limitations. This was an obser-
vational study that relied upon caregiver recall of health-
care utilization from birth to the time of the natural history 
study visit; therefore, actual healthcare burden may be un-
derrepresented. Another limitation is that most of the indi-
viduals in this study (92%) were under the age of 13 years, 
which inevitably underestimates the true burden of health-
care utilization over the lifetime of an individual with AS. 
The primary reason for the predominance of younger chil-
dren in our cohort was that co‐enrollment in other treat-
ment trials was restricted to participants of younger ages. 
Hence, the utilization reported in this study is less reflec-
tive of the needs of adults and adolescents. Similarly, the 
medical and seizure history is more reflective of younger 
individuals. For instance, we found that only 68% of the 
entire cohort had a history of clinical seizures. This is in 
contrast to the published clinical diagnostic criteria for AS, 
which states that seizures are observed in about 80% of AS 
individuals (Williams et al., 2006). The lower history of 
clinical seizure is mainly because the population is skewed 
toward younger individuals and seizures just may not have 
happened yet. Indeed, when data were examined by age, 
history of clinical seizures among 5  years and older was 
80% and among 13 years and older was 100%. The younger 
age can also explain differences in hospitalization rates 
between ours and other published studies as well as rela-
tively similar utilization across the two etiologies. Hence, 
future studies that analyze HRU and STU by age and that 
include older individuals are needed to assess changes in 
burden with age and to assess unmet needs among older 
individuals. Finally, the ASNHS did not capture all of the 
resources used by the individuals with AS such as outpa-
tient visits or use of communication devices (e.g. augmen-
tative and alternative communication, iPad™), which have 
become increasingly more prevalent to aid in communica-
tion (Wheeler, Sacco, & Cabo, 2017).
In conclusion, this is the first known published study to 
report HRU and STU among children with AS in the USA. 
The high rates of HRU and STU by individuals with AS high-
light the significant healthcare burden caused by this disorder 
in this age group. In addition, this is the first study to show 
that the healthcare burden was similar across the molecular 
etiologies among younger individuals with AS. However, 
additional studies need to be performed to understand how 
healthcare burden varies with age and among older individu-
als with AS to further evaluate the impact of AS on a broader 
population and the healthcare system.
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